Recent investigations have converged on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and DA neurotransmission. While GCGR activators are commonly employed for treating type 2 T2DM, their potential effects on motivation circuits, specifi